These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16708716)

  • 1. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for diabetes: pramlintide and exenatide.
    Jones MC
    Am Fam Physician; 2007 Jun; 75(12):1831-5. PubMed ID: 17619527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide and pramlintide: new therapies for diabetes.
    Want LL; Ratner R
    Int J Clin Pract; 2006 Dec; 60(12):1522-3. PubMed ID: 17109659
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes basics. Exenatide and pramlintide. New meds on the block.
    Griffin S; Borders J
    Diabetes Self Manag; 2006; 23(4):74-6, 79. PubMed ID: 16888865
    [No Abstract]   [Full Text] [Related]  

  • 5. New potential adjuncts to treatment of children with type 1 diabetes mellitus.
    Raman VS; Heptulla RA
    Pediatr Res; 2009 Apr; 65(4):370-4. PubMed ID: 19092720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapies for diabetes.
    Green DE
    Clin Cornerstone; 2007; 8(2):58-63; discussion 64-5. PubMed ID: 18357956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
    Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
    J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.
    Odegard PS; Setter SM; Iltz JL
    Diabetes Educ; 2006; 32(5):693-712. PubMed ID: 16971704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are you up-to-date on diabetes medications?
    Scemons D
    Nursing; 2007 Jul; 37(7):45-9; quiz 49-50. PubMed ID: 17603373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is pramlintide an adjunct to insulin therapy?
    Charles MA
    Diabetes Technol Ther; 2002; 4(2):190-2. PubMed ID: 12079622
    [No Abstract]   [Full Text] [Related]  

  • 13. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
    Edelman SV; Weyer C
    Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramlintide in the treatment of diabetes.
    Edelman SV; Darsow T; Frias JP
    Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.
    Ahrén B; Adner N; Svartberg J; Petrella E; Holst JJ; Gutniak MK
    Diabet Med; 2002 Sep; 19(9):790-2. PubMed ID: 12207819
    [No Abstract]   [Full Text] [Related]  

  • 18. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.
    Hoogwerf BJ; Doshi KB; Diab D
    Vasc Health Risk Manag; 2008; 4(2):355-62. PubMed ID: 18561511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramlintide: A new tool in diabetes management.
    Want LL; Ratner RE
    Curr Diab Rep; 2006 Nov; 6(5):344-9. PubMed ID: 17076994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.